Why the study?
To evaluate the value of serial C-reactive protein (CRP) measurements in predicting the risk of cardiovascular disease, cancer, and mortality.
Do initial and longitudinal changes in C-reactive protein predict the risk of cardiovascular disease, cancer, and mortality in the general population?
Do initial and longitudinal changes in C-reactive protein predict the risk of cardiovascular disease, cancer, and mortality in the general population?
Both initial levels and subsequent increases in C-reactive protein are significant predictors of future cardiovascular disease, cancer, and mortality in the general population.
Answers are grounded in this paper and cite their sources.
May support serial CRP monitoring for risk stratification; extends longitudinal data but leaves causal effects and interventions open.
OBJECTIVE: To evaluate the value of serial C-reactive protein (CRP) measurements in predicting the risk of cardiovascular disease (CVD), cancer, and mortality. METHODS: The analysis was performed using data from two prospective, population-based observational cohorts: the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study and the Framingham Heart Study (FHS). A total of 9253 participants had CRP measurements available at two examinations (PREVEND: 1997-1998 and 2001-2002; FHS Offspring cohort: 1995-1998 and 1998-2001). All CRP measurements were natural log-transformed before analyses. Cardiovascular disease included fatal and nonfatal cardiovascular, cerebrovascular and peripheral vascular events, and heart failure. Cancer included all malignancies except nonmelanoma skin cancers. Baseline CRP, as well as increase in CRP over time (ΔCRP), were associated with incident CVD (hazard ratio [HR]: 1.29 per 1-SD increase; 95% confidence interval [CI]: 1.29 to 1.47, and HR per 1-SD increase: 1.19; 95% CI: 1.09 to 1.29 respectively). Similar findings were observed for incident cancer (baseline CRP, HR: 1.17; 95% CI: 1.09 to 1.26; ΔCRP, HR: 1.08; 95% CI: 1.01 to 1.15) and mortality (baseline CRP, HR: 1.29; 95% CI: 1.21 to 1.37; ΔCRP, HR: 1.10; 95% CI: 1.05 to 1.16). CONCLUSION: Initial as well as subsequent increases in CRP levels predict future CVD, cancer, and mortality in the general population.
No takes yet. Share an insight, caveat, or question.
Suthahar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: